A share price of Keros Therapeutics Inc [KROS] is currently trading at $12.18, down -0.49%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KROS shares have gain 22.04% over the last week, with a monthly amount glided 6.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on January 21, 2025, when Cantor Fitzgerald downgraded its rating to a Neutral. Previously, Wedbush downgraded its rating to Neutral on January 17, 2025, and kept the price target unchanged to $15. On December 16, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $63 on the stock. Guggenheim downgraded its rating to a Neutral. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $47 on December 13, 2024. William Blair downgraded its rating to Mkt Perform for this stock on December 12, 2024. In a note dated December 12, 2024, TD Cowen downgraded an Hold rating on this stock.
Keros Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $9.12 and $72.37. Currently, Wall Street analysts expect the stock to reach $103.5 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $12.18 at the most recent close of the market. An investor can expect a potential return of 749.75% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Trailing Twelve Months sales for Keros Therapeutics Inc [NASDAQ:KROS] were 3.55M which represents 2027.27% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -59.39%, Pretax Profit Margin comes in at -52.69%, and Net Profit Margin reading is -52.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.38 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.93 points at the first support level, and at 11.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.43, and for the 2nd resistance point, it is at 12.68.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Keros Therapeutics Inc [NASDAQ:KROS] is 21.45. Further, the Quick Ratio stands at 21.45, while the Cash Ratio is 20.4. Considering the valuation of this stock, the price to sales ratio is 139.16, the price to book ratio is 0.86.
Transactions by insiders
Recent insider trading involved ADAR1 Capital Management, LLC, 10% Owner, that happened on Apr 09 ’25 when 0.93 million shares were purchased. Director, GORDON CARL L completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Director ORBIMED ADVISORS LLC sold 0.25 million shares on Aug 13 ’24.
